Our portfolio is focused on business sustainability. The pipeline comprises small molecules being developed for CNS indications in different stages of development; one candidate has human phase 2 data (CB2202) while another (CB2810) is being repurposed for a new indication. Three of the molecules are at the preclinical stage (CB0306, CB2233, and CB8411) and were shown efficacious in relevant disease models mitigating the risk of efficacy failure during development. They have a clear path for synthesis and are devoid of major side effects.
Cennerv Pharma presents a syndicated risk approach in its business model for drug development.